Você procurou por: monoaminooksidazs (Lituano - Inglês)

· monoaminooksidazs inhibitorius.
· monoamine oxidase inhibitors

paroksetino draudziama vartoti kartu su monoaminooksidazs (mao) inhibitoriais.
paroxetine is contraindicated in combination with monoamine oxidase inhibitors (maois) .

vartojant comtan negalima vartoti monoaminooksidazs (mao) inhibitori (antidepresantas) .
comtan should not be used together with other medicines that belong to the group ` monoamine oxidase inhibitors'( a type of antidepressant) .

-kartu su neselektyviaisiais monoaminooksidazs (mao-a ir mao-b) inhibitoriais (pvz.,
-concomitant use of stalevo with non-selective monoamine oxidase (mao-a and mao-b)

stalevo neturi bti skiriamas kartu su vaistais, priklausanciais monoaminooksidazs inhibitori (kiti vaistai nuo depresijos) grupei.
stalevo should not be used together with other medicines that belong to the group ` monoamine oxidase inhibitors'( a type of antidepressant) .

tasmar negalima skirti kartu su neselektyviais monoaminooksidazs (mao) inhibitoriais (pvz., fenelzinu ir tranilciprominu) .
tasmar should not be given in conjunction with non-selective monoamine oxidase (mao) inhibitors (e. g. phenelzine and tranylcypromine) .

ionsys nerekomenduojama vartoti pacientams, gydomiems monoaminooksidazs inhibitoriais (maoi) ir 14 dien po gydymo, nes pastarieji gali labai sustiprinti opioidini analgetik poveik, kurio nemanoma numatyti.
6 ionsys is not recommended for use in patients who have received monoamine oxidase (mao) inhibitors within 14 days because severe and unpredictable potentiation by mao inhibitors has been reported with opioid analgesics.

sios medziagos gali susilpninti insulino poreik: geriami antidiabetiniai vaistai, monoaminooksidazs inhibitoriai (maoi) , neselektyvs beta -blokatoriai, angiotenzin konvertuojancio fermento (akf) inhibitoriai, salicilatai ir alkoholis.
the following substances may reduce the insulin requirements:oral antidiabetic medicinal products, monoamine oxidase inhibitors (maoi) , non-selective beta-blocking agents, angiotensin converting enzyme (ace) inhibitors, salicylates and alcohol.